Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    132
    ...
ATC Name B/G Ingredients Dosage Form Price
J02AC01 PANZIMOL G Fluconazole - 100mg 100mg Capsule, hard 2,015,764 L.L
G01AX12 BRUMIXOL G Ciclopiroxolamine - 100mg 100mg Ovule 795,555 L.L
J02AC01 STABILANOL G Fluconazole - 100mg 100mg Capsule 1,432,331 L.L
R03DA05 AMINOPHYLLINE G Aminophylline - 100mg 100mg Tablet, scored 445,388 L.L
M02AA31 ROXONIN TAPE B Loxoprofen Sodium Hydrate - 100mg 100mg Patch 896,343 L.L
R03DA05 AMINOPHYLLINE CHILDREN G Aminophylline - 100mg 100mg Suppository 203,496 L.L
L01BC07 VIDAZA B Azacitidine - 100mg 100mg Injectable lyophilised powder 15,158,791 L.L
J01DD13 CEFODOX G Cefpodoxime (proxetil) - 100mg 100mg Tablet 434,061 L.L
J02AC02 FONGINOX G Itraconazole - 100mg 100mg Capsule 778,149 L.L
J01DD13 CEFPODOXIME ARROW LAB G Cefpodoxime (proxetil) - 100mg 100mg Tablet, film coated 499,909 L.L
J02AC02 FONGINOX G Itraconazole - 100mg 100mg Capsule 174,060 L.L
L01FG01 AVASTIN BioTech Bevacizumab - 100mg 100mg Injectable concentrated solution 24,533,456 L.L
J02AC02 ITRAZOL G Itraconazole - 100mg 100mg Capsule 149,167 L.L
L01BC07 AZACITIDINE NEAPOLIS G Azacitidine - 100mg 100mg Injectable lyophilised powder 9,401,575 L.L
J02AC02 ITRAZOL G Itraconazole - 100mg 100mg Capsule 559,038 L.L
L01BC07 AZACITIDINE SHILPA G Azacitidine - 100mg 100mg Injectable powder 7,350,062 L.L
J02AC02 TRACON G Itraconazole - 100mg 100mg Capsule 559,038 L.L
L01BC07 AZACITIDINE SPC G Azacitidine - 100mg 100mg Injectable powder 10,706,993 L.L
L04AD01 SANDIMMUN NEORAL SOFT GELATIN B Ciclosporin - 100mg 100mg Capsule, soft gelatin 8,264,592 L.L
L01BC07 MATURUS G Azacitidine - 100mg 100mg Injectable lyophilised powder 9,401,575 L.L
L01BC07 ZYDROME G Azacitidine - 100mg 100mg Injectable lyophilised powder 10,967,854 L.L
N05AH04 PMS-QUETIAPINE G Quetiapine fumarate - 100mg 100mg Tablet 1,890,786 L.L
L01XX52 VENCLEXTA B Venetoclax - 100mg 100mg Tablet L.L
N05AH04 QUETIAPINE/ GENEPHARM G Quetiapine - 100mg 100mg Tablet, film coated 1,569,608 L.L
N05AH04 SEROPINE 100 G Quetiapine fumarate - 100mg 100mg Tablet, film coated 1,996,950 L.L
C01BC04 FLECAINE B Flecainide acetate - 100mg 100mg Tablet, scored 878,873 L.L
C01BC04 FLECAINIDE ARROW LAB G Flecainide acetate - 100mg 100mg Tablet, scored 588,603 L.L
H02AB09 HYDROCORTISON VUAB G Hydrocortisone hydrogenosuccinate - 100mg 100mg Injectable dry powder for solution 147,823 L.L
J02AC04 NOXAFIL B Posaconazole - 100mg 100mg Tablet, gastroresistant 62,027,714 L.L
C01BC04 FLECAINIDE BIOGARAN L.P. G Flecainide acetate - 100mg 100mg Capsule, extended release 1,154,361 L.L
    ...
    132
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025